Sydney Airport to be removed from the S&P/ASX 200 Index
Filed with ASX · · 2 pages · English
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- 1st Patient Dosed ProstACT Prostate Cancer Therapy Program
- Appendix 4C and Activities Report for December 2021 Quarter
- Capital Raise Presentation
- Telix completes $175M placement and launches $25M SPP
- Targeted Alpha Therapy for Bladder Cancer 1st patient dosed
Later from Telix Pharmaceuticals
- Telix Granted Illuccix EU Regulatory Review Extension
- Commercial Distribution Agreement for Illuccix for Australia
- 2021 Full Year Results Presentation
- Cancellation of Share Purchase Plan
- ZIRCON Phase 3 Imaging Study Completes Targets Enrolment
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals